Heron Therapeutics Inc. (HRTX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Heron Therapeutics Inc. (NASDAQ: HRTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.30 (+6.27% 1D, market cap $52.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HRTX ranks #642 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRTX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 73.3%, and ROIC of -35.0%. By comparison, XLO (Xilio Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $52.8M) and PLRX (Pliant Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $53.2M). Among the 5-stock peer group, HRTX leads on earnings multiple (N/A) while HRTX leads on capital efficiency (-35.0% ROIC).
Per HRTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818033), Heron Therapeutics Inc. generated $154.9M in revenue (+7.4% YoY), -$20.0M in net income, and -$27.9M in free cash flow against $255.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While HRTX currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.33) and Max Pain ($0.32) forces dealer call-delta covering toward $1.66.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Heron Therapeutics Inc. (HRTX) surged +6.27% to $0.30, trading at 3% of its 52-week range ($0.26 – $1.58). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +7.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HRTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HRTX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Heron Therapeutics Inc. (HRTX) ranks #642 by composite RQD confidence (34/100, grade E) and #738 by equity capitalization ($52.7M). Within this direct 5-issuer industry benchmark cohort, HRTX leads on earnings valuation at N/A trailing P/E, while HRTX leads on capital efficiency and profitability with -35.0% ROIC and 73.3% gross margin. HYFT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with HRTX at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HRTX
ACTIVE
Heron Therapeutics Inc. | E | 34/100 | — | 73.3% | -35.0% | +6.27% | $52.7M | Benchmark Subject |
| XLO Xilio Therapeutics Inc. | E | 25/100 | — | — | -35.0% | -0.50% | $52.8M | /xlo-vs-hrtx → |
| PLRX Pliant Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -2.29% | $53.2M | /plrx-vs-hrtx → |
| TLPH Talphera Inc. | D- | 36/100 | — | — | -35.0% | -1.94% | $53.5M | /tlph-vs-hrtx → |
| HYFT MindWalk Holdings Corp. | D | 45/100 | — | — | — | -2.65% | $53.8M | /hyft-vs-hrtx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Heron Therapeutics Inc. (HRTX) reported GAAP revenue of $154.9M (+7.4% vs. FY2024 revenue of $144.3M , and -50.0% cumulative change since FY2023) , GAAP net income of -$20.0M, operating cash flow of -$27.6M, and free cash flow of -$27.9M (-15.2% YoY). On the balance sheet, HRTX closed FY2025 with $255.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $154.9M | -$20.0M | -$27.6M | -$27.9M | $255.9M | — |
| FY2024 (FY) | 2024-12-31 | $144.3M | -$14.0M | -$22.5M | -$24.2M | $233.1M | — |
| FY2023 (FY) | 2023-12-31 | $309.7M | -$111.0M | -$58.8M | -$58.8M | — | — |
As of 2026-11-03, Heron Therapeutics Inc. (NASDAQ: HRTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.30 (+6.27% 1D, market cap $52.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HRTX ranks #642 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRTX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 73.3%, and ROIC of -35.0%. By comparison, XLO (Xilio Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $52.8M) and PLRX (Pliant Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $53.2M). Among the 5-stock peer group, HRTX leads on earnings multiple (N/A) while HRTX leads on capital efficiency (-35.0% ROIC).
Per HRTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818033), Heron Therapeutics Inc. generated $154.9M in revenue (+7.4% YoY), -$20.0M in net income, and -$27.9M in free cash flow against $255.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
HRTX last traded at $0.30 (+6.27% on volume of 1,218,814 shares), positioning the stock -9.09% below its 50-day simple moving average ($0.33) and -56.52% below its 200-day simple moving average ($0.69). Across its 52-week range of $0.26 to $1.58, HRTX sits at the 3.0% percentile with a 14-day RSI of 37.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.34).
Heron Therapeutics Inc. (HRTX) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.30 (+6.27% 1D, market capitalization $52.7M).
Heron Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Per the market data, the company reports a gross margin of 73.3%, which indicates the economics of its sales are high at the gross level before operating costs.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Heron Therapeutics Inc. (HRTX) reported $154.9M in annual revenue (up from $144.3M in FY2024, +7.4% YoY) and -$20.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($309.7M revenue, -$111.0M net income) through FY2025, HRTX scaled operating cash flow to -$27.6M and free cash flow to -$27.9M, backed by $255.9M in total assets against $0 in total debt.
No upstream or downstream dependencies, sector correlations, or proprietary signal links are recorded for HRTX. A prospective investor should therefore treat second-order ripple analysis as unsupported by the current dataset.
Real-time company headlines, analyst actions, and sector developments for Heron Therapeutics Inc. (HRTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Heron Therapeutics Inc. (HRTX) market action, institutional positioning, and fundamental catalysts.
Long HRTX at $0.28 targeting $0.35. Revenue grew from $144.3M to $154.9M in FY 2025 while operating income improved from -$11.5M to -$2.5M, and institutional and options activity registers as the strongest RQD pillar at 11 / 20.. Institutional whale score is 10/20 and the risk/reward vs. the $0.26 52-week low is skewed heavily in favor of bulls.
@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (73.3%) holds, EPS grows into the multiple faster than bears think.
Sitting on the sidelines or leaning short HRTX above $0.28. Negative free cash flow of -$27.9M in FY 2025, ROIC of -35%, a Piotroski F-Score of 2 out of 9, and an insider conviction pillar at only 3 / 20 weigh on the RQD score of 37.. Until Fundamental Cash Engine (7/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.58.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: